There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Applied DNA Sciences (APDN – Research Report) and Synaptogenix (SNPX – Research Report) with bullish sentiments.
Applied DNA Sciences (APDN)
In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Applied DNA Sciences, with a price target of $6.00. The company’s shares closed last Tuesday at $3.55.
According to TipRanks.com, Vendetti is a 3-star analyst with an average return of
Applied DNA Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $7.00, representing an 110.8% upside. In a report issued on August 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.
See the top stocks recommended by analysts >>
Synaptogenix (SNPX)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Synaptogenix yesterday and set a price target of $14.00. The company’s shares closed last Tuesday at $8.52.
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of
Synaptogenix has an analyst consensus of Moderate Buy, with a price target consensus of $14.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APDN:
- Vroom Stock’s Blistering Momentum Could Run Out of Gas
- Crown Electrokinetics Reports Second Quarter 2022 Earnings and Announces First Customer Purchase Orders
- Aerojet Rocketdyne Opens Industry’s First SCEPS Manufacturing Facility for Next Generation Torpedo Propulsion
- Splash Beverage Group, Inc. To Present at Sidoti August Microcap Conference
- AFC Gamma Stock: A Double-Digit Dividend Yield to Consider
